ROSEVILLE, Calif., Sep 08, 2008 (BUSINESS WIRE) -- Dutton Associates updates its coverage of Vyteris (OTCBB:VYTR) maintaining a Speculative Buy rating and a $1 price target. The 13-page report by Dutton senior analyst Richard W. West, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg Professional, FactSet, Capital IQ, Zacks...

FAIR LAWN, N.J., Aug 05, 2008 (BUSINESS WIRE) -- Vyteris, Inc. (OTC BB: VYTR), manufacturer of the first U.S. Food and Drug Administration (FDA)-approved active patch transdermal drug delivery system, announced an initiative to identify and target candidate drugs in the pain management field that could potentially be delivered using Vyteris' active...

FAIR LAWN, N.J.--(BUSINESS WIRE)--Vyteris, Inc. (OTC BB: VYTR), manufacturer of the first FDA-approved active patch transdermal drug delivery system, received $2.5 million principal amount of financing effective on July 9, 2008 from Ferring Pharmaceuticals, Inc. (“Ferring”), which represented an advance on a potential milestone payment ...

FAIR LAWN, N.J., Jun 11, 2008 (BUSINESS WIRE) -- Vyteris, Inc. (OTCBB: VYHN), manufacturer of the first FDA-approved active patch transdermal drug delivery system, informed its shareholders of important plans to pursue an aggressive partnership and licensing strategy for its transdermal drug delivery technology, as well as restructuring of its boar...

FAIR LAWN, N.J., May 01, 2008 (BUSINESS WIRE) -- Vyteris, Inc. (OTCBB: VYHN), developer of the first FDA-approved active patch transdermal drug delivery system, announces the appointments of John E. Burrows and Susan P. Guerin to the company's board of directors, both of which became effective earlier in 2008. Burrows serves on the company's audit ...

FAIR LAWN, N.J., Jan 22, 2008 (BUSINESS WIRE) -- Citing a significant advance in drug delivery, Vyteris, Inc. (OTC BB: VYHN) and Ferring Pharmaceuticals today announced results from a completed Phase 1 clinical trial demonstrating that Vyteris' patented Smart Patch transdermal technology successfully delivered a peptide molecule in humans (multiple...

FAIR LAWN, NJ - (December 4, 2007) - Vyteris, Inc. (OTCBB: VYHN), manufacturer of LidoSite®, the first active transdermal patch approved by the U.S. Food and Drug Administration for the pain associated with blood draws (venipuncture), IV (intravenous) cannulations and laser ablation of superficial skin lesions, today announced the expected ass...

Dutton Associates initiates coverage of Vyteris (OTCBB:VYHN) with a Speculative Buy rating and a target price of $2.40. The 24-page report by Dutton senior analyst Richard West, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial por...

Vyteris, Inc. (OTCBB: VYHN) kicked off the nationwide commercial availability of its LidoSite(R) transdermal patch with the deployment of a specialty sales and marketing team dedicated to the promotion and sale of LidoSite into targeted physician specialty offices, including rheumatologists, oncologists, and ...

Vyteris Inc. (OTCBB: VYHN) today announced the completion of a new private placement financing transaction in which it raised $12.7 million in cash, for net proceeds of $11.4 million after legal and transactions costs of $1.3 million. This follows another financing round last October 2006 for $23.1 million. ...